BlackRock Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-4,608
| Closed | -$14K | – | 3785 |
|
|
2016
Q3 | $14K | Sell |
4,608
-1,189
| -21% | -$2.06K | ﹤0.01% | 3528 |
|
|
2016
Q2 | $9K | Sell |
5,797
-6,306
| -52% | -$14.4K | ﹤0.01% | 3605 |
|
|
2016
Q1 | $45K | Buy |
12,103
+837
| +7% | +$5.18K | ﹤0.01% | 3196 |
|
|
2015
Q4 | $114K | Sell |
11,266
-5,727
| -34% | -$68.9K | ﹤0.01% | 2865 |
|
|
2015
Q3 | $231K | Buy |
16,993
+2
| +0% | +$36 | ﹤0.01% | 2638 |
|
|
2015
Q2 | $322K | Sell |
16,991
-1,531
| -8% | -$33.1K | ﹤0.01% | 2497 |
|
|
2015
Q1 | $485K | Buy |
18,522
+2,777
| +18% | +$70.7K | ﹤0.01% | 2097 |
|
|
2014
Q4 | $330K | Sell |
15,745
-96,133
| -86% | -$2.42M | ﹤0.01% | 2302 |
|
|
2014
Q3 | $3.73M | Buy |
111,878
+51,528
| +85% | +$1.6M | ﹤0.01% | 1036 |
|
|
2014
Q2 | $1.94M | Sell |
60,350
-233,642
| -79% | -$8.7M | ﹤0.01% | 1186 |
|
|
2014
Q1 | $13.6M | Buy |
293,992
+13,221
| +5% | +$775K | 0.01% | 679 |
|
|
2013
Q4 | $19.9M | Sell |
280,771
-98,393
| -26% | -$7.52M | 0.02% | 561 |
|
|
2013
Q3 | $32.5M | Buy |
379,164
+363,755
| +2,361% | +$30.8M | 0.03% | 426 |
|
|
2013
Q2 | $976K | Buy |
+15,409
| New | +$818K | ﹤0.01% | 1392 |
|
BlackRock Advisors's AEGR Position: Q4 2016 in Review
BlackRock Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 4,608 shares — an estimated $14K sold.
BlackRock Advisors first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $32.5M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- BlackRock Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- BlackRock Advisors sold 4,608 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $14K.
- BlackRock Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- BlackRock Advisors's Aegerion Pharmaceuticals position peaked at $32.5M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.